Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis

Not Applicable

• Conditions: Determination of the Efficacy of Different Medications for Idiopathic Rhinitis; Safety and Tolerance of Different Medications for Idiopathic Rhinitis; Impact of Different Medications on Biomarkers of Idiopathic Rhinitis
• Interventions: Drug: 0.9% natural saline; Drug: Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.); Drug: Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)

• Registration Number: NCT04002349
• Lead Sponsor: Beijing Tongren Hospital

Brief Summary

Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.

Detailed Description

Not available

Study Timeline

• Status Verified: 2019-06
• Study First Submitted: 2019-06-27
• Study First Submitted QC: 2019-06-27
• Last Update Submitted: 2019-06-27
• Study First Posted: 2019-06-28
• Last Update Posted: 2019-06-28
• Study Start: 2019-07-01
• Primary Completion: 2019-12-31
• Study Completion: 2020-03-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Not younger than 18 years old
• Diagnosed as idiopathic rhinitis
• Signed and volunteered for the study

Exclusion Criteria

• Comorbid airway diseases including (but not limited to) upper airway infection, chronic rhinosinusitis, nasal polyps
• Allergic to the medicines about to study
• Having used oral glucocorticoids or antihistamine agents within 30 days of the enrollment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
A: Placebo group	0.9% natural saline	Treated by 0.9% Natural saline (NS) nasal spray: 2 sprays each side daily in the morning
B: Budesonide Nasal Spray (Rhinocort)	Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)	Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning
C: Levocabastine Nasal Spray (Livostine)	Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)	Treated by Levocabastine(Livostinet, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
D: Combined Treatment	Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)	Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning and Levocabastine(Livostinet, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning
D: Combined Treatment	Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)	Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning and Levocabastine(Livostinet, Shanghai Johnson \& Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning

Primary Outcome Measures

Name	Time	Method
Relief of bothersome symptoms	2 weeks	Determined by change of visual analog scale for symptoms

Trial Locations

Locations (2)

Yifan Meng; 🇨🇳 Beijing, Beijing, China

Beijing Tongren Hospital; 🇨🇳 Beijing, Beijing, China